George Scorsis

CO-FOUNDER & CHAIRMAN CORPORATE BOARD

George has 15 years experience leading companies in highly regulated industries to rapid growth, includ-ing alcohol, energy drinks and, most recently, medical cannabis. Formerly President of Red Bull Canada, he was instrumental in restructuring the organisation and growing the business to $150 MM in revenue.

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland’s top ranked business school.

Dr. Ben Sessa

CO-FOUNDER & CHIEF MEDICAL OFFICER

Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers. He is the author of psychedelic medical exploration books; The Psychedelic Renaissance (2012 and 2017) and To Fathom Hell or Soar Angelic (2015). He has recently completed research with Imperial College London exploring the world’s first MDMA-assisted therapy trial for the treatment of Alcohol Dependence Syndrome. Alongside Prof. David Nutt, Ben has also been a long term advocate of drug policy reform in the UK; believing that current laws hamper research and increase, rather than reduce, the burden of problematic drug use on individuals and society.

Prof. John Papastergiou

INDEPENDENT NON-EXECUTIVE DIRECTOR CORPORATE BOARD

Professor John Papastergiou is a highly regarded phar- macist and clinical research scientist who has served as an advisor to several leading pharmaceutical or- ganisations including Bayer, Pfizer, GSK, and Astra Zeneca. He holds faculty appointments at the schools of Pharmacy at both the University of Toronto and the University of Waterloo. In 2019, he was named by the International Forum on Advancement of Healthcare as one of the top 100 healthcare leaders globally.

Jonathan Held

CHIEF BUSINESS OFFICER

Jonathan is a chartered professional accountant, with CFO level experience for private / public companies.

Jonathan has worked in a number of sectors including technology, biotech and natural resources, both domestic and international, and has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings.

James Collins

CHIEF OPERATING OFFICER

James is a senior business leader and mental health champion with 17 years of experience with Accenture Strategy, 7 years as MD, designing and delivering corporate, digital and operating model strategies.

James holds a BSc and MPhil in Psychology from University College London (UCL).

Dr. Laurie Higbed

LEAD PSYCHOLOGIST

Laurie is an experienced clinical psychologist. Laurie has worked as a lead therapist on clinical trials using MDMA and psilocybin-assisted psychotherapy and has a special interest in working with complex trauma, addictions and the use of psychedelic therapy to treat a range of mental health difficulties.

Laurie is registered with the Health and Care Professions Council (HCPC) and is a member of the Association of Clinical Psychologists (ACPUK).

Prof. Celia Morgan

HEAD OF KETAMINE-ASSISTED THERAPY

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom.

Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship programme at Yale University. After competing her Ph.D Prof. Morgan worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.

Prof. Morgan also holds an Honorary Readership at University College London. Prof. Morgan is academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE).

Dr. Shaun McNulty

CHIEF SCIENCE OFFICER

Shaun is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of indus- try experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Da- vis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies. Shaun has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.

Steve Page

INDEPENDENT NON-EXECUTIVE DIRECTOR

Stephen Page has worked at Chief Executive and Board level in UK healthcare for over 30 year, most noticeably leading Priory Healthcare, the largest network of men- tal healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organisations in both public and private sectors including Oxleas NHS Trust in London, Nestor plc and Acorn Care and Education.

Prof. David Nutt

CHIEF RESEARCH OFFICER

David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books, including one for the general public, Drugs: Without The Hot Air, that won the Transmission Prize in 2014.

He is currently the President of the European Brain Council and Founding Chair of Drug Science. Previously he has been president of the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology. He broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.

Kate Butler

Chief Financial Officer

Kate is a Chartered Accountant with significant expe- rience of both UK and US public companies. Kate has worked across a number of sectors including phar- maceuticals and natural resources. Most recently Kate has held senior positions at Vectura Group plc, a FTSE 250 specialist inhalation contract development and manufacturing organisation, and Gilead Sciences Inc, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Kate has extensive experience of building strong finance teams and processes, and growing companies in new markets.

Gordo Whittaker

CHIEF MARKETING OFFICER

Gordo is a senior marketing and communications industry leader with over 10 years’ experience, build- ing, protecting and growing some of the world’s most famous brands, including Volkswagen and Land Rover, where he led their global advertising function.

Doriann Bailey

QUALITY, SAFETY & RISK LEAD

Doriann is passionate about the provision of high quality, safe, effective, caring, responsive and well led health- care services. She is a seasoned and highly effective strategic and operational senior professional. Doriann has over 30 years of clinical and managerial experience in various NHS and Independent organisations.
As well as being a Specialist Advisor (Governance) for The Care Quality Commission (CQC), Doriann is a quali- fied nurse and midwife.

Martyna Kabia

HR LEAD

Martyna is a highly motivated and career driven HR Pro- fessional with over 20 years’ proved ability gained in the NHS, higher education, Faith based, private and public sector. She is experienced in key areas of strategic HR management including recruitment and selection, em- ployee relations, employment law, analysis and report- ing, remuneration, job evaluation, project work, training, coaching, mentoring and HR consultancy.

Paul Carter

INDEPENDENT NON-EXECUTIVE DIRECTOR CORPORATE BOARD

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, having served as Executive Vice-President and Chief commercial Officer of Gilead Sciences Inc. He also was the head of GSK China amongst many others execu- tive positions. He currently sits on the board of several publicly listed and private bioscience companies.

Prof. Barbara J. Mason

ADVISOR CLINICAL ADVISORY BOARD

Barbara J. Mason, Ph.D. is Director of the Pearson Cen- ter for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Pearson Family Professor in the Department of Mo- lecular Medicine at The Scripps Research Institute, La Jolla, CA. Dr. Mason’s work in medication development for the treatment of substance use disorder has been recognized globally. Prof. Mason conducted the semi- nal studies identifying nalmefene as having therapeutic potential for alcohol dependence.

Prof. Harriet de Wit

ADVISOR PRE-CLINICAL ADVISORY BOARD

Prof. de Wit is the Professor and Director of the Human Behavioral Pharmacology Laboratory in the Depart- ment of Psychiatry and Behavioral Neuroscience at the University of Chicago. In addition to her role as Principal Investigator for several NIH-funded research projects, Dr. de Wit serves as Field Editor for the journal Psycho- pharmacology. She is also a consultant to the Food and Drug Administration (FDA).

Ann Mithoefer, BSN

ADVISOR CLINICAL ADVISORY BOARD

Ann Mithoefer, B.S.N., is a Registered Nurse focused primarily on training and supervising therapists con- ducting MAPS-sponsored clinical trials, as well as continuing to conduct some MAPS research sessions. Between 2004 and 2018, she and her husband, Michael Mithoefer, M.D., completed two of the six MAPS-spon- sored Phase II clinical trials testing MDMA-Assisted Therapy for PTSD, as well a study providing MDMA-As- sisted sessions for therapists who have completed
the MAPS Therapist Training, and a pilot study treating couples with MDMA-Assisted Therapy combined with Cognitive-Behavioural Conjoint Therapy.

Dr. Michael Mithoefer

ADVISOR CLINICAL ADVISORY BOARD

Michael Mithoefer, M.D., began collaborating with MAPS in 2000 on the first U.S. Phase II clinical trial of MDMA-Assisted Therapy. He has since conducted two of the six MAPS sponsored Phase II clinical trials testing MDMA-Assisted Therapy for PTSD, as well a study providing MDMAassisted sessions for therapists who have completed the MAPS-sponsored MDMA Therapy Training Program, and a pilot study treating couples with MDMA-Assisted Therapy combined with Cognitive-Behavioural Conjoint Therapy.

Prof. Stephen Husbands

ADVISOR PRE-CLINICAL ADVISORY BOARD

Professor Husbands is professor of medicinal chem- istry in Department of Pharmacy and Pharmacology at the University of Bath. His research has focused on the development and therapeutic potential of central nervous system targeted ligands, particularly those interacting with multiple receptors.